子痫前期筛查:美国预防服务工作组证据报告与系统评价
该系统评价为美国预防服务工作组汇总1990年至2016年的证据,纳入21项研究(13982例参与者),未发现直接比较筛查人群与非筛查人群有效性的研究;一项美国试验(n=2764)发现减少产前检查次数在获益与危害上无差异,但对罕见严重结局把握度不足。16个风险预测模型中有5个判别能力良好或更好(c统计量>0.80),但在最大、最适用的验证队列中阳性预测值仅4%,且未报告校准。无症状初级保健人群中无尿液筛查性能研究;疑似子痫前期妇女的尿蛋白检测准确性差异大(灵敏度22%-100%,特异度36%-100%)。结论认为证据有限,外部验证模型适用性有限且缺乏常规使用所需的校准和临床实施数据。
要点
- 无研究直接比较筛查人群与非筛查人群的子痫前期筛查有效性,筛查获益与危害的证据有限。
- 一项美国试验(n=2764)发现减少产前检查次数在获益或危害上无差异,但对罕见严重结局把握度不足。
- 16个风险预测模型中有5个判别能力良好或更好(c统计量>0.80),但最大、最适用验证队列中阳性预测值仅4%,且未报告校准。
- 无症状初级保健人群无尿液筛查性能研究;疑似子痫前期妇女尿蛋白检测灵敏度22%-100%、特异度36%-100%,异质性高。
- 外部验证的风险预测模型适用性有限,缺乏常规使用所需的校准和临床实施数据。
适用人群与场景
- 孕妇,涵盖常规产前筛查场景及因疑似子痫前期接受评估的妇女。
- 证据纳入英文试验和观察性研究,包括外部验证的预测模型。
- 无症状初级保健人群中无尿液筛查性能研究。
诊断标准与关键阈值
- 子痫前期定义为妊娠20周后高血压并蛋白尿或其他多系统受累证据。
研究设计与关键结果
- 21项研究(13982例参与者)纳入系统评价;未进行Meta分析,因研究存在临床和统计学异质性。
- 无研究直接比较筛查人群与非筛查人群的筛查有效性;一项美国试验(n=2764)发现减少产前检查次数在获益或危害上无差异,但对罕见严重结局把握度不足。
- 一项前后对照非劣效性队列研究(n=1952)比较特定指征尿蛋白筛查与常规筛查,未发现减少尿液筛查试验的危害。
- 4项研究(n=7123)报告16个风险预测模型的外部验证性能,其中5个模型对子痫前期预测的c统计量>0.80,但在最大、最适用的验证队列中阳性预测值仅4%;未报告校准。
- 14项研究(n=1888)在疑似子痫前期妇女中评估尿蛋白检测性能,灵敏度22%-100%、特异度36%-100%,所用检测、纳入标准和蛋白尿患病率(8.7%-93.8%)存在高度统计学和临床异质性。
证据类型、等级与局限
- 证据类型:为美国预防服务工作组进行的系统评价。
- 局限性:未进行Meta分析,因纳入研究存在临床和统计学异质性;无研究直接比较筛查人群与非筛查人群;风险预测模型未报告校准;需进一步研究以更好地指导基于风险的筛查方法并改进筛查策略。
对床旁实践的改变
- 外部验证的风险预测模型适用性有限且缺乏校准和临床实施数据,不支持常规使用。
- 证据不足以估计子痫前期筛查的获益与危害以及不同筛查方法在整个孕期中的检测性能。
- 作者认为需进一步研究以更好地指导基于风险的筛查方法并改进筛查策略。
指南或共识出处
- 美国预防服务工作组证据报告与系统评价(JAMA)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Preeclampsia is a complex disease of pregnancy with sometimes serious effects on maternal and infant morbidity and mortality. It is defined by hypertension after 20 weeks' gestation and proteinuria or other evidence of multisystem involvement.
OBJECTIVE: To systematically review the benefits and harms of preeclampsia screening and risk assessment for the US Preventive Services Task Force.
DATA SOURCES: MEDLINE, PubMed, and Cochrane Central Register of Controlled Trials databases from 1990 through September 1, 2015. Surveillance for new evidence in targeted publications was conducted through October 5, 2016.
STUDY SELECTION: English-language trials and observational studies, including externally validated prediction models, of screening effectiveness, benefits, and harms from routine preeclampsia screening during pregnancy.
DATA EXTRACTION AND SYNTHESIS: Independent dual review of article abstracts and full texts against a priori inclusion criteria. Meta-analysis was not performed because of clinical and statistical heterogeneity of included studies.
MAIN OUTCOMES AND MEASURES: Maternal and infant health outcomes, including eclampsia, stroke, stillbirth, preterm birth, and low birth weight; screening and risk prediction test performance; harms of screening and risk assessment.
RESULTS: Twenty-one studies (13 982 participants) were included. No studies directly compared the effectiveness of preeclampsia screening in a screened population vs an unscreened population; 1 US trial (n = 2764) found no difference in benefits or harms with fewer prenatal visits but was underpowered for rare, serious outcomes. For harms, a before-after comparison cohort noninferiority study of urine protein screening for specific indications compared with routine screening (n = 1952) did not identify harms with fewer urine screening tests. Four studies (n = 7123) reported external validation performance of 16 risk prediction models, 5 of which had good or better discrimination (c statistic >0.80) for prediction of preeclampsia, and positive predictive values of 4% in the largest, most applicable validation cohorts. Calibration was not reported despite being a key model performance measure. There were no studies of urine screening test performance conducted in asymptomatic primary care populations; 14 studies of protein urine test performance among women being evaluated for suspected preeclampsia (n = 1888) had wide-ranging test accuracy (sensitivity, 22%-100%; specificity, 36%-100%) and high statistical and clinical heterogeneity in tests used, eligibility criteria, and proteinuria prevalence (8.7%-93.8%).
CONCLUSIONS AND RELEVANCE: Evidence to estimate benefits and harms of preeclampsia screening and the test performance of different screening approaches over the course of pregnancy was limited. Externally validated risk prediction models had limited applicability and lacked calibration and clinical implementation data needed to support routine use. Further research is needed to better inform risk-based screening approaches and improve screening strategies, given the complex pathophysiology and clinical unpredictability of preeclampsia.
参考来源
- Henderson JT, Thompson JH, Burda BU, et al. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017. PMID: 28444285. doi:10.1001/jama.2016.18315
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。